Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
VVV's surge drives default model provider, with Base ecosystem token POD's market cap soaring to 82 million dollars

VVV's surge drives default model provider, with Base ecosystem token POD's market cap soaring to 82 million dollars

ChaincatcherChaincatcher2026/05/09 02:45
Show original

According to ChainCatcher, GMGN monitoring indicates that the Base ecosystem token POD (Dolphin) saw a significant surge this morning, reaching a peak market capitalization of 82 million US dollars before retreating to 76.4 million US dollars. The 24-hour increase stands at 130%, with on-chain trading volume during the same period reaching approximately 2.9 million US dollars.

The catalyst for this price rise may be the strong performance of VVV. As an AI model development and DePIN project, Dolphin provides the “Dolphin Mistral 24B Venice Edition,” which is the default uncensored AI model on the Venice platform. As the core model provider, POD has seen its price rise accordingly.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56